(Health-NewsWire.Net, November 03, 2016 ) -A review of the Integrilin based on information derived from company and industry-specific sources -Coverage of the Marketed data of the Integrilin on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification -Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Integrilin with location details -Patent Expiry Timeline and Exclusivity Details -Route of Synthesis of the API -Global Forecasted Sales Figure to 2018 -Qualitative and quantitative assessment of market space -SWOT Analysis
Reasons to buy
-Evaluate the marketing status and exclusivity details of Integrilin to exploit opportunities for generic drug development opportunities. -Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Integrilin. -API intelligence over Integrilin and gaining primary intelligence over Active Ingredients manufacturers across the globe. -Understanding the chemical route of synthesis of Integrilin. -Uncovering opportunities in the rapidly growing the US market -Stay ahead of competition by understanding the changing competitive landscape -Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential -Make more informed business decisions from insightful and in-depth analysis of the drug's performance -Obtain sales forecast for currently marketed drug for to 2018
1. DelveInsight Report Introduction 2. Integrilin Overview 2.1 Market Competition 2.3 Competitors in Development 3 Global Sales Assessment 3.1 Historical Sales of Integrilin 3.2 Forecasted Sales of Integrilin 4 Product Description 4.1 Mechanism of Action 4.2 Pharmacodynamic Properties 4.3 Pharmacokinetic Properties 5 Marketed Details 5.1 United States 5.2 Europe 6 Patent Information 6.1 Patent Numbers and Expiry Details 6.2 Patent and Exclusivity Expiry Assessment United States (US) 6.3 Patent Details 7 Route of Synthesis 8 Global API Manufacturers Assessment 8.1 The United States Drug Master File (US DMF) 8.2 The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF) 8.3 The Active Pharmaceutical Ingredient (API) Manufacturers in China 8.4 The Active Pharmaceutical Ingredient (API) Manufacturers in India 9 Generic Players 10 The Pipeline Coverage 11 Clinical Trials Information 11.1 Clinical Trials by Zone 12 Company Profile 12.1 Company Summary 12.2 Company Financials 13 SWOT Analysis 14 References 15 Appendix 16 Methodology 17 Consulting Services 18 About DelveInsight 19 Contact Us 20 Disclaimer